Alexion Pharmaceuticalsの収入
Alexion Pharmaceuticalsの収入 は何ですか。
Alexion Pharmaceuticals Inc.の収入 は681.800M$です。
収入 の定義は何ですか。
普通株主に帰属する当期純利益は、純利益から優先配当金を差し引いた金額です。優先配当
Net income available to common shareholders are the profits remaining after the company pays all of its suppliers, employees, service providers, creditors, and preferred shareholders. In other words, this is revenue less all expenses and preferred dividends. The number measures common shareholders' claim on the company's cash flows.
NASDAQのセクタHealth Careにおける収入 の企業と比べるAlexion Pharmaceuticals
Alexion Pharmaceuticalsは何をしますか。
Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. As a leader in rare diseases for more than 25 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D) as well as the first and only approved Factor Xa inhibitor reversal agent. In addition, the company is developing several mid-to-late-stage therapies, including a copper-binding agent for Wilson disease, an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases and an oral Factor D inhibitor as well as several early-stage therapies, including one for light chain (AL) amyloidosis, a second oral Factor D inhibitor and a third complement inhibitor. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology, ophthalmology and acute care. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.
Alexion Pharmaceuticalsと類似の収入
- Western Superconducting Technologies Coの収入 は679.770M¥です。
- London Stock Exchange Plcの収入 は681.000M£です。
- Suncorpの収入 は681.000MAUD$です。
- London Stock Exchange plcの収入 は681.000M£です。
- Interactive Brokers Incの収入 は681.000M$です。
- Wonderla Holidaysの収入 は681.537M₨です。
- Alexion Pharmaceuticalsの収入 は681.800M$です。
- Wheels Indiaの収入 は682.200M₨です。
- Oshkosh Corpの収入 は682.500M$です。
- Ralph Lauren Corpの収入 は682.800M$です。
- Xの収入 は682.877M¥です。
- Allison Transmission Incの収入 は684.000M$です。
- CITの収入 は684.700M$です。